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Introduction
In 1986, a new clinical disease in cattle was
recognised in the United Kingdom (UK). It was
classified as a progressive neurological condi-
tion similar to scrapie of sheep and goats, and
was named bovine spongiform encephalopathy
(BSE) (Wells et al. 1987). Other transmissible
spongiform encephalopathies (TSE) had been
described before the occurrence of BSE,
namely scrapie of sheep and goats (first ob-
served/described as a clinical entity around
1730), a transmissible mink encephalopathy
(TME, 1947), a chronic wasting disease of
North American deer and elk (CWD, 1978),
and the human TSEs sporadic Creutzfeldt-
Jakob disease (sCJD, 1920), Gerstmann-Sträus-
sler-Scheinker Syndrom (GSS, 1928), Kuru
(1957), and fatal familiar insomnia (FFI, 1986).
These TSEs can arise spontaneously (sCJD), be
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inherited (FFI, GSS), or are naturally or acci-
dentally transmitted (scrapie, Kuru, CWD,
BSE). Some of them possess several of these
properties (Hartsough & Burger 1965, De-
twiler 1992, Kimberlin 1992, Williams & Young
1992, Will 1993, Hoinville 1996, Spraker et al.
1997, Prusiner 1998a). There is an ongoing
discussion whether BSE should be classified as
infectious, contagious, or zoonotic, and if it fits
the definition of a production disease. The ob-
jective of this work is to briefly describe the
main characteristics of TSEs, to review the epi-
demiology of BSE, and to address the question
of how to classify BSE. 
Characteristics of prion diseases
All known TSEs are characterised by an accu-
mulation of prions ("proteinacious infectious
particles", PrP) and vacuolation of the CNS in
the final stages of the disease. PrPC is routinely
synthesised by various cells, and is metabolised
(digested) by proteinase K (enzymes). The in-
fectious prion protein, denoted PrPSc or PrPres,
is partly proteinase K resistant. It forms
oligomers, accumulates mainly in the cells of
the CNS, and results in the specific histopatho-
logical changes observed in the differed TSEs
(Prusiner 1998b). Both PrPC and PrPSc have the
same aminoacid sequence, but they have differ-
ent three-dimensional structures: PrPC in 42%
is composed of structures called alpha helices,
and has only a few beta sheets (Lopez Garcia et
al. 2000). The infectious PrPSc has only 30% al-
pha helices, and more than 40% beta sheets.
The transition of PrPC to PrPSc, based on the
prion dimer theory of Prusiner, occurs by merg-
ing of a normal (healthy) and an infectious
prion molecule to form a PrPC-PrPSc het-
erodimer, in which the normal PrPC molecule is
restructured into PrPSc. After separation of the
2 molecules, 2 new PrPSc homodimers have
been created which again can convert healthy
PrPC molecules (Prusiner 1998b). It still is de-
bated whether PrPSc and TSE infectivity are one
and the same, or if there is an additional factor
"X" (protein, virion, virus?) besides exposure
to PrPSc required to result in a TSE infection
(Telling et al. 1995). 
TSE infectivity is difficult to destroy (decon-
taminate). The most efficient method is appli-
cation of wet heat (autoclaving) after treatment
with sodium hydroxide (1-2M NaOH). Appli-
cation of dry heat will conserve TSE infectivity,
and temperatures up to 600°C have been de-
scribed as insufficient to fully eliminate it from
brain tissue cubes (Brown et al. 1990, 2000).
The commonly used methods to treat MBM
during rendering (133°C at 3 bars for 20 min-
utes) will reduce TSE infectivity by at least
98%, but not always by 100% (Taylor et al.
1998, 1999, Schreuder et al. 1998, Taylor 1999,
2000). TSE infectivity, once excreted, can sur-
vive in the environment (soil) for several years,
as has been demonstrated with the scrapie agent
(Brown & Gajdusek 1991).
Epidemiology of BSE
The origin of BSE (as a cattle disease) is an is-
sue of controversial debate, but it is unlikely
that this controversy will ever be resolved. The
most widely accepted hypothesis is that cattle
BSE originated from sheep scrapie, i.e. that one
of the British sheep scrapie strains was recycled
with MBM to cattle, and was (or became during
recycling) infectious for cattle. After this adap-
tation, on-going intra-species recycling caused
the BSE epidemic in British cattle (Schreuder
1993, Taylor 1995). Alternatively, a sponta-
neous mutation in the genome coding for the
PrP gene, similar to sporadic CJD in humans,
could have resulted in a TSE strain either in
sheep or in cattle that was subsequently infec-
tious for – and recycled to – cattle. The intro-
duction of BSE from a wildlife population
seems to be a less realistic hypothesis. Large
scale recycling of BSE infectivity in the UK be-
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came possible after 1970 when changes in the
tallow (fat) extraction during MBM rendering
from solvent-based (wet, higher temperatures)
to pressure-based (dry, lower temperatures) al-
lowed the infectious agent to survive (Wile-
smith et al. 1991, Kimberlin 1992).
Epidemiological studies on the clinical BSE
cases diagnosed in UK in 1986 and 1987 high-
lighted the increased risk for BSE on farms that
had fed cattle concentrates containing meat and
bone meal (MBM). The recycling of ruminant-
derived MBM to ruminants and other farm ani-
mals via concentrate feed was common practice
in the UK and other countries (Fig. 1) (Wile-
smith et al. 1988, 1992a, 1992b, Hoinville et al.
1995, Anderson et al. 1996). Cattle concen-
trates contained up to 6% protein of either ani-
mal or plant origin. As a consequence of the
studies linking MBM use to BSE, this inclusion
of MBM into ruminant feed was banned in the
UK in July 1988, and in Switzerland in Decem-
ber 1990. These bans resulted in a significant
reduction of new infections in cattle born after
their implementation, thereby highlighting the
importance of controlling this exposure route
(Fig. 2). The secondary increase in BSE cases
by birth cohort seen in Switzerland might be the
result of an increase in the number of infected
cattle reaching clinical levels of disease, and in-
crease of MBM imports from neighbouring Eu-
ropean countries, and increase in the surveil-
lance activities since 1999, or a combination of
those factors.
BSE cases born after these MBM bans (denoted
BAB cases) documented the presence of other
infection routes besides routine inclusion of
MBM in cattle concentrates. Cross-contamina-
tion of cattle feed with feed for pigs and poul-
try during production, transportation or stor-
age, and cross-exposure of cattle to pig or
poultry feed on mixed-species farms were sug-
gested as additional infection routes (Fig. 1)
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Figure 1. BSE infection cycle and exposure of other species to products of cattle origin. Solid arrows (––)in-
dicate direct exposure to cattle-derived products (cattle-derived food, cattle feed), broken  arrows (–·–·) indicate
exposure to feed produced for pigs or poultry, and dotted arrows (·····) indicate an exposure to feed produced for
pets (dogs and cats).
(Hoinville 1994, Hoinville et al. 1995). The Sci-
entific Steering Committee (SSC) of the Euro-
pean Commission in a geographic BSE risk as-
sessment exercise (GBR) listed several risk
factors for BSE propagation (spread within a
cattle population) including the structure and
intensity of the cattle population and other live-
stock populations, production and use of rumi-
nant-derived meat-and-bone meal (including
feed bans), the use of specified risk material
(SRM) and carcasses (including SRM bans)
and the rendering industry (structure, technol-
ogy, rendering parameters) (Alban et al. 2000,
SSC 2000a). The most important measures to
prevent exposure of cattle to BSE are the ban of
feeding ruminant protein back to cattle ("MBM
ban"), the exclusion of all high risk material
such as brain and spinal cord of cattle and cat-
tle carcasses from MBM production ("SRM
ban"), the treatment of produced MBM at
133°C and 3 bars for 20 min (EU standard), and
the prevention of cross contamination during
feed production and use. Blocking of the known
and suspected feed-related routes of BSE trans-
mission has resulted in a documented decline in
the number of new infections in subsequent
birth cohorts in the UK, in Switzerland (Fig. 2),
and in other countries. Due to the long incuba-
tion time of BSE, however, it takes several years
until the effectiveness of implemented mea-
sures to prevent new BSE infections can be re-
liably assessed. 
Pathogenesis
Experimental oral inoculation of calves and se-
quential slaughter done in the UK documented
that BSE infectivity was only present in the
anatomical region of the Peyers patches of the
distal ileum at distinct time points during the in-
cubation period, and in the central nervous sys-
tem (CNS: brain, spinal cord, dorsal root gan-
glia) late in incubation (few months before
clinical disease) and during clinical disease. In
cattle, BSE infectivity has not been docu-
36 M. G. Doherr
Acta vet. scand. Suppl. 98 - 2003
Figure 2. Proportion of all British (––) and Swiss (––) BSE cases with known birth date (y axis) by birth
year (x axis). The immediate drop in cases in the year after the first ban of feeding meat and bone meal to cattle
(UK July 1988, CH Dec 1990, as indicated by the arrows) highlight the strong (causal) association between
MBM feeding and BSE (data as of August 2001).
mented in meat, milk, blood, urine, lymph
nodes or any other tissue besides the CNS and
the distal ileum wall (Middleton & Barlow
1993, Taylor et al. 1995, Wells et al. 1994,
1998). One report in which sternal bone mar-
row isolated from a clinical BSE case in one of
the experimentally exposed mice induced a
TSE was never reproduced, and was later spec-
ulated to have been cross-contamination. With-
out excretion of the infectious agent during in-
cubation or clinical disease, direct horizontal
transmission (from infected to susceptible cat-
tle) does not occur. BSE infectivity levels of
CNS tissue from clinically diseased cattle have
been titrated in cattle, and there is evidence that
0.1 gram of brain tissue is sufficient to orally in-
fect calves with BSE. Direct intracerebral inoc-
ulation of the infectious agent into susceptible
mice strains seems to be 500 to 1000 times
more efficient than oral exposure of the mice,
and this method is used extensively to study the
distribution of BSE infectivity in various tis-
sues of experimentally infected animals or field
cases, and to differentiate between BSE and
other TSE strains. 
BSE spread and surveillance
Introduction of the BSE agent into recipient
countries has occurred by live animal trade, and
by direct or indirect trade between BSE-ef-
fected and BSE-free countries with MBM and
other products potentially containing BSE in-
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Table 1. Implementation of mandatory reporting for bovine spongiform encephalopathy (BSE), year of the first
BSE cases, implementation of a targeted screening, total BSE case numbers in 2000 and 2001, and assessment
of the overall BSE surveillance system in the European Union Member States and Switzerland as of December
21, 2001. 
Adult Mandatory First reported BSE Detected BSE cases Surveillance system
cattle reporting case (OIE) (OIE) meets OIE requirements
Country pop.1 since




Austria 1.0 1991 - - 0 1 1 No
Belgium 1.5 1990 - 1997 9 46 65 Yes
Denmark 0.9 1990 1992 2000 1 6 7 No
Finland 0.4 1990 - - 0 1 1 Yes
France 11.0 1990 2000 1991 162 258 499 No
Germany 6.6 1990 1992 2000 7 125 132 Yes
Greece 0.3 ? - 2001 0 1 1 No data available
Ireland 3.4 1989 1989 1989 149 220 799 No
Italy 3.4 1991 1994 2001 0 48 48 Yes
Luxembourg 0.1 1990 - 1998 0 0 1 No
Netherlands 1.8 1990 - 1997 2 20 28 Yes
Portugal 0.8 1990 1990 1994 163 67 591 Yes
Spain 3.4 1990 - 2000 2 82 84 No
Sweden 0.7 1989 - - 0 0 0 Yes
UK2 5.3 1988 - 1986 1443 ~800 181642 Yes
Switzerland 0.9 1990 - 1990 33 42 408 Yes
Sources: OIE (www.oie.int), various European Commission internet sites, the GBR opinions and the GBR country reports.
1Million cattle above 24 months of age (Source: Eurostat).
2United Kingdom: data from 1987 include year 1986; data for 2001 are incomplete.
3Data for 2001 might be incomplete due to delayed reporting to the OIE.
fectivity (Hörnlimann et al. 1994, Nathanson et
al. 1997, Schreuder et al. 1997). The GBR done
by the EU indicated a rather wide geographic
distribution of the disease, and this has been
confirmed by the surveillance activities imple-
mented since the year 2000. Domestic BSE
cases by now have been detected in all but one
of the EU Member States (Sweden) as well as in
Switzerland (Table 1). In addition, in 2001 Slo-
vakia (4 cases), Japan (3), the Czech Republic
(2) and Slovenia (1) experienced their first do-
mestic BSE cases. Based on the GBR, addi-
tional countries such as Albania, Estonia, Hun-
gary, Lithuania, Poland and Cyprus are
expected to harbour BSE-infected cattle (SSC
2000a, 2001).
BSE case detection until 1998 was restricted to
the mandatory reporting and subsequent inves-
tigation of clinical suspect cases ("passive"
surveillance). Since 1999 EU-validated fast
screening assays such as the Prionics check
Western blot or the BioRad Platelia ELISA
have become available as a surveillance tool for
targeted "high-risk" cohorts ("active" surveil-
lance). This type of combined passive and ac-
tive BSE surveillance was implemented in
Switzerland in January of 1999, and is manda-
tory for the EU member states since January 1,
2001 (Doherr et al. 1999, 2001, 2002, Schaller
et al. 1999, SSC 2000b, Schiermeier 2001).
Data from the Swiss surveillance indicated that
mandatory suspect reporting captured less than
50% of the detectable BSE cases that were re-
moved from the population (Doherr et al. 1999,
2001). In other countries passive surveillance
might have completely missed a low number of
clinical BSE cases for some periods of time. In
recent years, however, an increase also in the
number of clinical BSE cases was seen in con-
tinental Europe (Fig. 3) in addition to the cases
detected by the passive surveillance. The com-
bination of passive and active surveillance
components therefore seem essential to reliably
assess the BSE status of a given country or re-
gion. However, the EU-validated screening as-
says rely on the post mortem detection of PrPSc
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Figure 3. Proportion of all British (––), Swiss (––) and other European countries combined (––) clini-
cal BSE cases (y axis) by year of reporting (x axis). The figures for 2001 were extrapolated from the case num-
bers observed until November 24, 2001.
in brain tissue (homogenate), and are validated
only for cattle with clinical BSE (Moynagh &
Schimmel 1999, Schaller et al. 1999, Oesch et
al. 2000, Deslys et al. 2001). No BSE test is
available for detection of animals during early
incubation, and we have to assume that a con-
siderable number of such cattle leaves the pop-
ulation undetected. Some ante mortem tests
have been announced in the media, however,
none has been commercialised so far.
Transmission of BSE to other species
Transmission of BSE to other species is possi-
ble. This has been documented in experimental
infection of several species, but also in the ob-
served FSE epidemic in domestic cats (over 90
cases in the UK reported since 1990), in rumi-
nants and large cats kept in British zoos, and by
the epidemic of the new variant of Creutzfeldt-
Jakob disease (vCJD) in humans with over 100
cases in the UK and 4 cases reported from
France so far (Pearson et al. 1991, Wyatt et al.
1991, Wells & McGill 1992, Schreuder 1994,
Collinge et al. 1996, Will et al. 1996, Hill et al.
1997).
BSE can be orally transmitted to sheep and
goats where it results in a TSE very similar to
scrapie (Foster et al. 1993, 1996). No field
cases of BSE in sheep have yet been diagnosed,
however, differentiation to sheep scrapie is only
possible by strain typing in mice bioassays,
which takes several years to perform. Attempts
to orally infect pigs or poultry with BSE failed
so far (Dawson et al. 1990, Done 1990, Mel-
drum 1990).
Conclusions
BSE is a new disease in cattle. Infectivity can
be titrated, and the disease has been transmitted
to the same and to other species including cats
and humans. This classifies BSE as infectious
and zoonotic. However, even cattle in the final
stages of (clinical) disease do not actively ex-
crete the infectious agent, and horizontal trans-
mission comparable with that of foot-and-
mouth disease (FMD), classical swine fever
(CSF) or even sheep scrapie does not occur; the
disease therefore is not considered to be conta-
gious. The term "production diseases" tradi-
tionally was used exclusively for metabolic dis-
eases that were induced by management
practices. More recently, the definition of pro-
duction diseases has been widened to include
other traits such as infertility, and multifactorial
diseases such as mastitis and lameness that
might involve infectious agents but that are ex-
acerbated by nutritional or management factors
(Nir Markusfeld 2001). BSE, which is caused
by an infectious agent (even though some "in-
fectiologists" might not agree to classify prion
diseases as such) and is dependent on manage-
ment factors, would fit into the broader defini-
tion of production diseases. This, however,
could be true for the majority of diseases that
currently affect our animal production systems.
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